Access To Medicines Innovation: Seven Points To A Sustainable System

The Boston Consulting Group convened a roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to reach consensus on how to finance the cost of health care. The group's working paper considers various approaches to financing high-quality care, with an initial emphasis on advocating for change among payers in Europe.

A key economic challenge confronting countries that serve as the market base for life sciences enterprises is how to finance the cost of health care – sustainably, in a way that combines increased access to medicines with continued innovation in new technologies. Last year, the Boston Consulting Group (BCG) convened an informal roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to try to do just that. The goal was to reach out, consult and build a forward-looking consensus on how the desire for innovation can be reconciled to the capacity of society, payers and patients to pay for it. From these exchanges, the group drafted a working paper considering various approaches to expanding resources to finance high-quality care, with an initial emphasis on advocating for change among payers in Europe.

At the suggestion of In Vivo, the roundtable obtained agreement to pursue these ideas jointly with DIA, the global association...

More from Market Access

More from In Vivo